In situ revascularization with silver-coated polyester grafts to treat aortic infection: Early and midterm results

被引:85
作者
Batt, M
Magne, JL
Alric, P
Muzj, A
Ruotolo, C
Ljungstrom, KG
Garcia-Casas, R
Simms, M
机构
[1] Hop St Roche, Dept Vasc Surg, F-06006 Nice, France
[2] Hosp La Trouche, Dept Vasc Surg, Grenoble, France
[3] Hop A Villeneuve, Dept Vasc Surg, Montpellier, France
[4] Hop Cardarelli, Dept Vasc Surg, Naples, Italy
[5] Kirurgiska Kliniken, Dept Surg, Danderyd, Sweden
[6] Pontevedra Hosp, Dept Vasc Surg, Pontevedra, Spain
[7] Univ Birmingham, Selly Oak Hosp, Dept Vasc Surg, Birmingham, W Midlands, England
关键词
D O I
10.1016/S0741-5214(03)00554-8
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose: In this prospective study we analyzed the immediate and midterm outcome in patients with abdominal aorta infection (mycotic aneurysm, prosthetic graft infection) managed by excision of the aneurysm or the infected vascular prosthesis and in situ replacement with a silver-coated polyester prosthesis. Methods: From January 2000 to December 2001, 27 consecutive patients (25 men, 2 women; mean age, 69 years) with an abdominal aortic infection were entered in the study at seven participating centers. Infection was managed with either total (n = 18) or partial (n = 6) excision of the infected aorta and in situ reconstruction with an InterGard Silver (IGS) collagen and silver acetate-coated polyester graft. Assessment of outcome was based on survival, limb salvage, persistent or recurrent infection, and prosthetic graft patency. Results: Twenty-four patients had prosthetic graft infections, graft-duodenal fistula in 12 and graft-colonic fistula in 1; and the remaining 3 patients had primary aortic infections. Most organisms cultured were of low virulence. The IGS prosthesis was placed emergently in 11 patients (41%). Mean follow-up was 16.5 months (range, 3-30 months). Perioperative mortality was 15%; all four patients who died had a prosthetic graft infection. Actuarial survival at 24 months was 85%. No major amputations were noted in this series. Recurrent infection developed in only one patient (3.7%). Postoperative antibiotic therapy did not exceed 3 months, except in one patient. No incidence of prosthetic graft thrombosis was noted during follow-up. Conclusion: Preliminary results in this small series demonstrate favorable outcome with IGS grafts used to treat infection in abdominal aortic grafts and aneurysms caused by organisms with low virulence. Larger series and longer follow-up will be required to compare the role of IGS grafts with other treatment options in infected fields.
引用
收藏
页码:983 / 989
页数:7
相关论文
共 41 条
[11]   USE OF AN ANTIBIOTIC-BONDED GRAFT FOR INSITU RECONSTRUCTION AFTER PROSTHETIC GRAFT INFECTIONS [J].
COLBURN, MD ;
MOORE, WS ;
CHVAPIL, M ;
GELABERT, HA ;
QUINONESBALDRICH, WJ .
JOURNAL OF VASCULAR SURGERY, 1992, 16 (04) :651-660
[12]   INFECTED INFRARENAL AORTIC-ANEURYSMS - WHEN IS INSITU RECONSTRUCTION SAFE [J].
FICHELLE, JM ;
TABET, G ;
CORMIER, P ;
FARKAS, JC ;
LAURIAN, C ;
GIGOU, F ;
MARZELLE, J ;
ACAR, J ;
CORMIER, JM .
JOURNAL OF VASCULAR SURGERY, 1993, 17 (04) :635-645
[13]   Comparison of the resistance to infection of rifampin-bonded gelatin-sealed and silver/collagen-coated polyester prostheses [J].
Goëau-Brissonnière, OA ;
Fabre, D ;
Leflon-Guibout, V ;
Di Centa, I ;
Nicolas-Chanoine, MH ;
Coggia, M .
JOURNAL OF VASCULAR SURGERY, 2002, 35 (06) :1260-1263
[14]   TREATMENT OF VASCULAR GRAFT INFECTION BY IN-SITU REPLACEMENT WITH A RIFAMPIN-BONDED GELATIN-SEALED DACRON GRAFT [J].
GOEAUBRISSONNIERE, O ;
MERCIER, F ;
NICOLAS, MH ;
BACOURT, F ;
COGGIA, M ;
LEBRAULT, C ;
PECHERE, JC .
JOURNAL OF VASCULAR SURGERY, 1994, 19 (04) :739-744
[15]   Graft-related complications after abdominal aortic aneurysm repair: Reassurance from a 36-year population-based experience [J].
Hallett, JW ;
Marshall, DM ;
Petterson, TM ;
Gray, DT ;
Bower, TC ;
Cherry, KJ ;
Gloviczki, P ;
Pairolero, PC .
JOURNAL OF VASCULAR SURGERY, 1997, 25 (02) :277-284
[16]   In situ replacement of infected aortic grafts with rifampicin-bonded prostheses: The Leicester experience (1992 to 1998) [J].
Hayes, PD ;
Nasim, A ;
London, NJM ;
Sayers, RD ;
Barrie, WW ;
Bell, PRF ;
Naylor, AR .
JOURNAL OF VASCULAR SURGERY, 1999, 30 (01) :92-98
[17]   INSITU ALLOGRAFT REPLACEMENT OF INFECTED INFRARENAL AORTIC PROSTHETIC GRAFTS - RESULTS IN 43 PATIENTS [J].
KIEFFER, E ;
BAHNINI, A ;
KOSKAS, F ;
RUOTOLO, C ;
LEBLEVEC, D ;
PLISSONIER, D .
JOURNAL OF VASCULAR SURGERY, 1993, 17 (02) :349-356
[18]   Treatment of vascular graft infection by in situ replacement with cryopreserved aortic allografts:: An experimental study [J].
Knosalla, C ;
Goëau-Brissonnière, O ;
Leflon, V ;
Bruneval, P ;
Eugène, M ;
Pechère, JC ;
Koskas, F ;
Nicolas, MH ;
Leschi, JP ;
Gerota, J ;
Kieffer, E .
JOURNAL OF VASCULAR SURGERY, 1998, 27 (04) :689-698
[19]   Limitations in the use of rifampicin-gelatin grafts against virulent organisms [J].
Koshiko, S ;
Sasajima, T ;
Muraki, S ;
Azuma, N ;
Yamazaki, K ;
Chiba, K ;
Tachibana, M ;
Inaba, M .
JOURNAL OF VASCULAR SURGERY, 2002, 35 (04) :779-785
[20]   Arteries from human beings are less infectible by Staphylococcus aureus than polytetrafluoroethylene in an aortic dog model [J].
Koskas, F ;
GoeauBrissonniere, O ;
Nicolas, MH ;
Bacourt, F ;
Kieffer, E .
JOURNAL OF VASCULAR SURGERY, 1996, 23 (03) :472-476